Facible’s Q-LAAD technology can signal the presence of a target molecule

Q-LAAD

The Evolution Of Aptamer Technology

The basis for our Q-LAAD technology platform are our revolutionary fluorogenic-logic aptamers (FLAs) which can be programed to signal the presence of nearly any target molecule. The result being a revolutionary new mechanism for the detection of the viruses that cause disease. This mechanism enables the creating of diagnostic tests that combine hospital-grade accuracy with point-of-care speed and ease of use.

Unparalleled Adaptability

Tests developed using the Q-LAAD technology ecosystem designed to be plug-and-play, requiring minimal adaptation time associated with new test development and we can quickly design tests that detect a range of molecules.

Hospital-Grade Performance

In recent clinical trials, our Q-LAAD SARS-CoV-2 test demonstrated a combination of speed, accuracy, & ease-of-use that cannot be achieved with legacy testing technologies (PCR, antigen, etc.). Tests take less than 5 minutes of analyzer time and still yield 97% sensitivity and 100% specificity*

*This data has not been verified by the FDA or any other regulatory body.

Optimized Usability

Q-LAAD technology can be adapted to a variety of testing formats. Although our testing ecosystem will be adapted to a point-of-care format, Q-LAAD technology can be used to develop tests for use in hospital labs with commercially available analyzers that fit within standard medical laboratory workflows, requiring minimal training or new expertise.

A New Biodiagnostic Paradigm

In addition to our revolutionary Q-LAAD test, we are developing a proprietary analyzer enabling simple plug-and-play tests that can be administered at the point of care. These point-of-use Q-LAAD tests allow us to deliver on our mission to provide lab-grade quality diagnostics to those who are in the most need regardless of geography or socioeconomic status.

Be a part of the revolution

We are currently raising capital via a Regulatory A+ securities offering. As an early-stage investor, you can help Facible revolutionize diagnostic testing for people around the world. For a limited time, early investors have the opportunity to earn one bonus share for every share purchased.

Invest Now

Do you have questions about Facible? Read our FAQs below

What is Q-LAAD?

Q-LAAD stands for Quantum-Logic Aptamer Analyte Detection and it is our patent-pending technology we’ve been developing over the past 6 years. Q-LAAD is an antigen detection system that uses aptamer technology to reveal the presence of viral antigens. Q-LAAD can be adapted to nearly any diagnostic testing format without sacrificing speed, accuracy, or ease-of-use, a common tradeoff with current diagnostic testing technologies.

How do Q-LAAD tests work?

Q-LAAD technology enables a fluorogenic logic aptamer to cause a dim fluorophore to become bright only when the aptamer is bound to the intended target.

How is Q-LAAD different than other biodiagnostic tests such as PCR, Isothermal Amplification, ELISA, etc.?

Q-LAAD tests differ from other testing methodologies in a few important ways:

Q-LAAD tests are sensitive enough to detect even trace amounts of a given target molecule, so there is no time-consuming amplification required to see results. Therefore, results from Q-LAAD tests are near-instantaneous.
Q-LAAD tests are specific enough to work with various types of samples and sample collection media such as blood, saliva, urine, etc.
Q-LAAD tests are much simpler and easier to use than other biodiagnostic tests, minimizing the margin for user and/or machine error.

Do Q-LAAD tests require any special, costly equipment?

No. Q-LAAD tests can be run on commercially available COMS analyzers and plate readers. We are currently working on our own point-of-care analyzer which will make Q-LAAD tests even more efficient and easy to use.

Why is Q-LAAD a better testing method for COVID-19?

We have developed a SARS-CoV-2 proof-of-concept test that has shown very promising results in our own clinical trials. Our Q-LAAD SARS-CoV-2 test excelled in three key areas:

Accuracy: : Q-LAAD tests meet or exceed a minimum threshold of 95% accuracy putting it on par with the most accurate (PCR) tests currently available.
Speed: Q-LAAD tests routinely deliver results in less than 5 minutes (and often near instantly) without sacrificing accuracy.
Throughput: Q-LAAD tests require minimal preparation and or specialized training. and can be run on a standard plate reader in minutes enabling technicians to process hundreds of tests in an hour.

What are the applications for Q-LAAD tests?

We are currently adapting our Q-LAAD platform to develop a 30+ pathogen respiratory testing panel that will allow healthcare professionals to quickly diagnose and treat the most common diseases such as influenza, SARS-CoV-2, human metapneumovirus, RSV, etc. In addition to a variety of medical diagnostic tests, we will be developing Q-LAAD tests for use across a wide range of industries including Agricultural, Regulatory, Pharmaceutical, and Veterinary just to name a few.

Are you guys crazy?

Nope. Not crazy. Just audacious.

Stay Connected.